Aug 20, 2025 • Benzinga
SOMEWHAT-BULLISH
Looking Into Verona Pharma's Recent Short Interest - Verona Pharma ( NASDAQ:VRNA )
Verona Pharma's VRNA short percent of float has fallen 39.84% since its last report. The company recently reported that it has 2.47 million shares sold short, which is 2.99% of all regular shares that are available for trading.
Aug 12, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
All You Need to Know About Verona Pharma ( VRNA ) Rating Upgrade to Buy
Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aug 11, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.
Aug 11, 2025 • Zacks Commentary
NEUTRAL
Merck Stock Down 4% Since Q2 Results: How to Play the Stock
Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.
Aug 07, 2025 • Motley Fool
SOMEWHAT-BULLISH
Ligand ( LGND ) Q2 Revenue Jumps 15%
Ligand Pharmaceuticals ( NASDAQ:LGND ) , a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7, 2025. The company exceeded analyst estimates with non-GAAP EPS of $1.60 ( consensus: $1.42 ) and reported revenue ...
Aug 07, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million ( previously $180 million - $200 million ) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 ( previously $6.00 - $6.25 )